<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097746</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0186</org_study_id>
    <secondary_id>NCI-2018-01832</secondary_id>
    <secondary_id>2009-0186</secondary_id>
    <nct_id>NCT01097746</nct_id>
  </id_info>
  <brief_title>First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer</brief_title>
  <official_title>A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well first-line treatment of bevacizumab, carboplatin, and&#xD;
      paclitaxel work in treating participants with stage III- IV ovarian, primary peritoneal and&#xD;
      fallopian tube cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the&#xD;
      ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin&#xD;
      and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing&#xD;
      the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      bevacizumab, carboplatin, and paclitaxel as first-line treatment may work better at treating&#xD;
      ovarian, primary peritoneal, and fallopian tube cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether patients with newly diagnosed ovarian, primary peritoneal, and&#xD;
      fallopian tube cancers when treated with bevacizumab, carboplatin, and weekly paclitaxel can&#xD;
      tolerate at least 4 cycles of therapy regardless of delay or dose modification.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the efficacy of bevacizumab combined with carboplatin and weekly paclitaxel in&#xD;
      patients with newly diagnosed ovarian, primary peritoneal, and fallopian tube cancers, as&#xD;
      measured by progression-free survival.&#xD;
&#xD;
      II. To evaluate the response rate in patients with newly diagnosed ovarian, primary&#xD;
      peritoneal, and fallopian tube cancers when treated with bevacizumab, carboplatin, and weekly&#xD;
      paclitaxel.&#xD;
&#xD;
      TRANSLATIONAL RESEARCH OBJECTIVES:&#xD;
&#xD;
      I. To assess the predictive value of a set of angiogenic genes whose expression correlates&#xD;
      with progression-free survival of patients with epithelial ovarian, peritoneal primary or&#xD;
      fallopian tube cancer treated with bevacizumab, carboplatin, and weekly paclitaxel.&#xD;
&#xD;
      II. To assess the relationship among cytokines/chemokines, angiogenesis factors, novel&#xD;
      targets of interest and clinical outcome including tumor response and progression-free&#xD;
      survival in patients treated with bevacizumab, carboplatin, and weekly paclitaxel.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive paclitaxel intravenously (IV) over 3 hours on days 1, 8 and 15 and&#xD;
      carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive&#xD;
      bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 14, 2010</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success defined as a patient completing at least 4 cycles of combination therapy</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Fallopian Tube Clear Cell Adenocarcinoma</condition>
  <condition>Fallopian Tube Endometrioid Adenocarcinoma</condition>
  <condition>Fallopian Tube Mucinous Adenocarcinoma</condition>
  <condition>Fallopian Tube Serous Adenocarcinoma</condition>
  <condition>Fallopian Tube Transitional Cell Carcinoma</condition>
  <condition>Fallopian Tube Undifferentiated Carcinoma</condition>
  <condition>FIGO Stage III Ovarian Cancer</condition>
  <condition>FIGO Stage IIIA Ovarian Cancer</condition>
  <condition>FIGO Stage IIIA1 Ovarian Cancer</condition>
  <condition>FIGO Stage IIIA1(i) Ovarian Cancer</condition>
  <condition>FIGO Stage IIIA1(ii) Ovarian Cancer</condition>
  <condition>FIGO Stage IIIA2 Ovarian Cancer</condition>
  <condition>FIGO Stage IIIB Ovarian Cancer</condition>
  <condition>FIGO Stage IIIC Ovarian Cancer</condition>
  <condition>FIGO Stage IVA Ovarian Cancer</condition>
  <condition>FIGO Stage IVB Ovarian Cancer</condition>
  <condition>Malignant Ovarian Brenner Tumor</condition>
  <condition>Ovarian Clear Cell Adenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mucinous Adenocarcinoma</condition>
  <condition>Ovarian Seromucinous Carcinoma</condition>
  <condition>Ovarian Serous Adenocarcinoma</condition>
  <condition>Ovarian Transitional Cell Carcinoma</condition>
  <condition>Ovarian Undifferentiated Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Primary Peritoneal Serous Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive paclitaxel IV over 3 hours on days 1, 8 and 15 and carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a histologic diagnosis of epithelial ovarian cancer, peritoneal primary&#xD;
             carcinoma or fallopian tube cancer; FIGO stage III and IV defined surgically at the&#xD;
             completion of initial abdominal surgery and with appropriate tissue available for&#xD;
             histologic evaluation. The minimum surgery required is an abdominal surgery providing&#xD;
             tissue for histologic evaluation and establishing and documenting the primary site and&#xD;
             stage, as well as a maximal effort at tumor debulking.&#xD;
&#xD;
          2. (continued from no. 1) Those patients with stage III cancer in which the largest&#xD;
             maximal diameter of any residual tumor implant at the completion of this initial&#xD;
             surgery is no greater than 1 cm will be defined as optimal; all others will be defined&#xD;
             as suboptimal.&#xD;
&#xD;
          3. The histologic features of the tumor must be compatible with a primary MÃ¼llerian&#xD;
             epithelial adenocarcinoma. Patients with the following histologic epithelial cell&#xD;
             types are eligible: Serous adenocarcinoma, Endometrioid adenocarcinoma, Mucinous&#xD;
             adenocarcinoma, Undifferentiated carcinoma, Clear cell adenocarcinoma, Mixed&#xD;
             epithelial carcinoma, Transitional cell, Malignant Brenner's Tumor, Adenocarcinoma&#xD;
             N.O.S. Patients may have co-existing fallopian tube carcinoma in-situ so long as the&#xD;
             primary origin of invasive tumor is ovarian, peritoneal or fallopian tube.&#xD;
&#xD;
          4. Patients must be entered no later than 12 weeks after initial surgery performed for&#xD;
             the combined purpose of diagnosis, staging and cytoreduction.&#xD;
&#xD;
          5. Patients with measurable and non-measurable disease are eligible. Patients may or may&#xD;
             not have cancer-related symptoms.&#xD;
&#xD;
          6. Patients in this trial may receive ovarian estrogen +/- progestin replacement therapy&#xD;
             as indicated at the lowest effective dose(s) for control of menopausal symptoms at any&#xD;
             time, but not progestins for management of anorexia while on protocol directed&#xD;
             therapy.&#xD;
&#xD;
          7. Patients with an ECOG Performance Status of 0, 1, or 2.&#xD;
&#xD;
          8. Patients must have normal organ and marrow function as defined below: leukocytes&#xD;
             &gt;3,000/mcL; absolute neutrophil count &gt;1,500/mcL; platelets &gt;100,000/mcL; total&#xD;
             bilirubin &lt;1.5 X institutional upper limits of normal; AST(SGOT)/ALT(SGPT) &lt;2.5 X&#xD;
             institutional upper limit of normal; Alkaline phosphatase (AP) &lt;2.5 X institutional&#xD;
             upper limit of normal; creatinine &lt;1.5X institutional upper limit of normal OR&#xD;
             creatinine clearance &gt;50 mL/min/1.73 m2 for patients with creatinine levels above&#xD;
             institutional normal&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with borderline epithelial ovarian tumor (formerly &quot;tumors of low malignant&#xD;
             potential&quot;) or recurrent invasive epithelial ovarian, primary peritoneal or fallopian&#xD;
             tube cancer treated with surgery only are not eligible. Patients with a prior&#xD;
             diagnosis of a borderline tumor that was surgically resected and who subsequently&#xD;
             develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian&#xD;
             tube cancer are eligible, provided that they have not received prior chemotherapy for&#xD;
             any ovarian tumor.&#xD;
&#xD;
          2. Patients who have received prior radiotherapy to any portion of the abdominal cavity&#xD;
             or pelvis are excluded. Prior radiation for localized cancer of the breast, head and&#xD;
             neck, or skin is permitted, provided that it was completed more than three years prior&#xD;
             to registration, and the patient remains free of recurrent or metastatic disease.&#xD;
&#xD;
          3. Patients who have received prior chemotherapy for any abdominal or pelvic tumor&#xD;
             including neo-adjuvant chemotherapy for their ovarian, primary peritoneal or fallopian&#xD;
             tube cancer are excluded. Patients may have received prior adjuvant chemotherapy for&#xD;
             localized breast cancer, provided that it was completed more than three years prior to&#xD;
             registration, and that the patient remains free of recurrent or metastatic disease.&#xD;
&#xD;
          4. Patients who have received any targeted therapy (including but not limited to&#xD;
             vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management&#xD;
             of their epithelial ovarian or peritoneal primary cancer.&#xD;
&#xD;
          5. Patients who are currently participating or planning to participate in an experimental&#xD;
             drug study other than a Genentech-sponsored bevacizumab cancer study or who are&#xD;
             receiving other investigational agents.&#xD;
&#xD;
          6. Patients with synchronous primary endometrial cancer, or a past history of primary&#xD;
             endometrial cancer, are excluded, unless all of the following conditions are met:&#xD;
             Stage not greater than IB; no more than superficial myometrial invasion, without&#xD;
             vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary&#xD;
             serous, clear cell or other FIGO Grade 3 lesions.&#xD;
&#xD;
          7. With the exception of superficial basal cell and superficial squamous (skin) cell,&#xD;
             carcinoma in situ of the cervix and other specific malignancies as noted above,&#xD;
             patients with other invasive malignancies who had (or have) any evidence of the other&#xD;
             cancer present within the last five years or whose previous cancer treatment&#xD;
             contraindicates this protocol therapy are excluded.&#xD;
&#xD;
          8. Patients with acute hepatitis or active infection that requires parenteral&#xD;
             antibiotics.&#xD;
&#xD;
          9. Patients with serious non-healing wound, ulcer, or untreated bone fracture. This&#xD;
             includes a history of abdominal fistula or gastrointestinal perforation within 6&#xD;
             months prior to Day 1. Patients with granulating incisions healing by secondary&#xD;
             intention with no evidence of fascial dehiscence or infection are eligible but require&#xD;
             weekly wound examinations until closure.&#xD;
&#xD;
         10. Patients with active bleeding or pathologic conditions that carry high risk of&#xD;
             bleeding, such as known bleeding disorder, coagulopathy (in the absence of therapeutic&#xD;
             anticoagulation), or tumor involving major vessels.&#xD;
&#xD;
         11. History of hemoptysis (&gt;/=1/2 teaspoon of bright red blood per episode) within 1 month&#xD;
             prior to Day 1.&#xD;
&#xD;
         12. Patients with history or evidence upon physical examination of CNS disease, including&#xD;
             primary brain tumor, seizures not controlled with standard medical therapy, any brain&#xD;
             metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic&#xD;
             attack (TIA) or subarachnoid hemorrhage within six months of the first date of&#xD;
             treatment on this study.&#xD;
&#xD;
         13. Patients with clinically significant cardiovascular disease. This includes: 1)&#xD;
             Uncontrolled hypertension, defined as systolic &gt; 140 mm Hg or diastolic &gt; 90 mm Hg; 2)&#xD;
             Myocardial infarction or unstable angina &lt; 6 months prior to registration; 3) New York&#xD;
             Heart Association (NYHA) Grade II or greater congestive heart failure; 4) Serious&#xD;
             cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial&#xD;
             fibrillation with controlled ventricular rate&#xD;
&#xD;
         14. (continued from no. 13) CTCAE Grade 2 or greater peripheral vascular disease (at least&#xD;
             brief (&lt;24 hrs) episodes of ischemia managed non-surgically and without permanent&#xD;
             deficit); Prior history of hypertensive crisis or hypertensive encephalopathy;&#xD;
             Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to Day 1&#xD;
&#xD;
         15. Patients with known hypersensitivity to Chinese hamster ovary cell products or other&#xD;
             recombinant human or humanized antibodies&#xD;
&#xD;
         16. Patients with known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
         17. Patients with clinically significant proteinuria at screening as demonstrated by urine&#xD;
             protein:creatinine (UPCR) ratio &gt;/= 1.0 at screening. The UPCR has been found to&#xD;
             correlate directly with the amount of protein excreted in a 24 hour urine collection.&#xD;
             Specifically, a UPCR of 1.0 is equivalent to 1.0 gram of protein in a 24 hour urine&#xD;
             collection. Obtain at least 4 ml of a random urine sample in a sterile container (does&#xD;
             not have to be a 24 hour urine). Send sample to lab with request for urine protein and&#xD;
             creatinine levels [separate requests].&#xD;
&#xD;
         18. (continued from no. 17) The lab will measure protein concentration (mg/dL) and&#xD;
             creatinine concentration (mg/dL). The UPCR is derived as follows: protein&#xD;
             concentration (mg/dL)/creatinine (mg/dL).&#xD;
&#xD;
         19. Patients with or with anticipation of invasive procedures as defined below: Major&#xD;
             surgical procedure within 28 days of initiating bevacizumab or major procedures&#xD;
             anticipated during the course of the study. This includes, but is not limited to&#xD;
             abdominal surgery (laparotomy or laparoscopy) prior to disease progression, such as&#xD;
             colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or&#xD;
             second look surgery.&#xD;
&#xD;
         20. (continued from no. 19) Core biopsy or other minor surgical procedure, excluding&#xD;
             placement of a vascular access device, within 7 days prior to the first date of&#xD;
             bevacizumab therapy&#xD;
&#xD;
         21. Patients with ECOG Performance Grade of 3 or 4&#xD;
&#xD;
         22. Patients who are pregnant (positive pregnancy test) or nursing. Use of effective means&#xD;
             of contraception (men and women) in subjects of child-bearing potential. To date, no&#xD;
             fetal studies in animals or humans have been performed. The possibility of harm to a&#xD;
             fetus is likely. Bevacizumab specifically inhibits VEGF, which is responsible for&#xD;
             formation of new blood vessels during development, and antibodies can cross the&#xD;
             placenta. Therefore, bevacizumab should not be administered to pregnant women.&#xD;
&#xD;
         23. (continued from no. 22) Subjects will be apprised of the large potential risk to a&#xD;
             developing fetus. It is not known whether bevacizumab is excreted in human milk.&#xD;
             Because many drugs are excreted in human milk, bevacizumab should not be administered&#xD;
             to nursing women. Patients of childbearing potential must agree to use contraceptive&#xD;
             measures during study therapy and for at least six months after completion of&#xD;
             bevacizumab therapy.&#xD;
&#xD;
         24. Patients under the age of 18.&#xD;
&#xD;
         25. Patients who have received prior therapy with any anti-VEGF drug, including&#xD;
             bevacizumab.&#xD;
&#xD;
         26. Patients with clinical symptoms or signs of gastrointestinal obstruction and who&#xD;
             require parenteral hydration and/or nutrition.&#xD;
&#xD;
         27. Patients with medical history or conditions not otherwise previously specified which&#xD;
             in the opinion of the investigator should exclude participation in this study.&#xD;
&#xD;
         28. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
         29. Known HIV-positive patients on combination antiretroviral therapy are ineligible&#xD;
             because of the potential for pharmacokinetic interactions with bevacizumab. In&#xD;
             addition, these patients are at increased risk of lethal infections when treated with&#xD;
             marrow-suppressive therapy. Appropriate studies will be undertaken in patients&#xD;
             receiving combination antiretroviral therapy when indicated.&#xD;
&#xD;
         30. Inability to comply with study and/or follow-up procedures&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Sood</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Bay Area</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Regional Care Center-The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Adenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

